2022
ANNUAL AWARDS GALA
THURSDAY • APRIL 28
Thank you for joining us in person, for the first time since 2019, for SWHR’s 32nd Annual Awards Gala to celebrate the achievements of trailblazers advancing women’s health care and their representation in education and research. Tonight, we are thrilled to honor three champions of women’s health: Dr. Wanda Barfield, Dr. Sudip S. Parikh, and Pfizer. These extraordinary leaders have each made significant contributions to their fields by improving maternal health care and outcomes, mentoring and advancing women and minorities in STEM education and research, and working in the lab to produce a life-saving vaccine during a global pandemic. We appreciate you joining us in celebrating these champions and their achievements.

As we look toward a post-pandemic world, we have the opportunity to address longstanding disparities and inequities in health care access, medical education, and clinical trials, particularly for women, that have been underscored during the COVID pandemic. As a result of the pandemic and continued gaps we see in women’s health, SWHR is launching the Women’s Health Equity Initiative, which will highlight statistics on women’s health and will engage communities on solutions to improve health equity for women across multiple disease states, conditions, and life stages. The first phase of the Initiative is focused on Alzheimer’s disease, bone health, maternal health, and menopause. Through the creation of a unique roadmap and video testimonials, featuring caregivers, patients, and clinicians, SWHR is working to end women’s health disparities based on age, race, ethnicity, geography, and among caregivers. We invite you to join us in these efforts. To learn more and support the Women’s Health Equity Initiative, visit swhr.org/healthequity.

We extend our sincere appreciation for the generous support from our sponsors and partners — we cannot do this important work without you. Because of your support, SWHR is able to continue advocating for prioritized investments in women’s health research and supports innovation and investment in therapies, diagnostics, and devices, with the ultimate goal of improving gender equity, ending health disparities, and improving and transforming women’s health across the lifespan.

Again, we would like to thank our sponsors, partners, and guests for your ongoing support and for your work to improve women’s health. Enjoy the evening!

Sincerely,

Kathryn G. Schubert, MPP, CAE
President and Chief Executive Officer

Dear Friends and Guests,

Thank you for joining us in person, for the first time since 2019, for SWHR’s 32nd Annual Awards Gala to celebrate the achievements of trailblazers advancing women’s health care and their representation in education and research. Tonight, we are thrilled to honor three champions of women’s health: Dr. Wanda Barfield, Dr. Sudip S. Parikh, and Pfizer. These extraordinary leaders have each made significant contributions to their fields by improving maternal health care and outcomes, mentoring and advancing women and minorities in STEM education and research, and working in the lab to produce a life-saving vaccine during a global pandemic. We appreciate you joining us in celebrating these champions and their achievements.

As we look toward a post-pandemic world, we have the opportunity to address longstanding disparities and inequities in health care access, medical education, and clinical trials, particularly for women, that have been underscored during the COVID pandemic. As a result of the pandemic and continued gaps we see in women’s health, SWHR is launching the Women’s Health Equity Initiative, which will highlight statistics on women’s health and will engage communities on solutions to improve health equity for women across multiple disease states, conditions, and life stages. The first phase of the Initiative is focused on Alzheimer’s disease, bone health, maternal health, and menopause. Through the creation of a unique roadmap and video testimonials, featuring caregivers, patients, and clinicians, SWHR is working to end women’s health disparities based on age, race, ethnicity, geography, and among caregivers. We invite you to join us in these efforts. To learn more and support the Women’s Health Equity Initiative, visit swhr.org/healthequity.

We extend our sincere appreciation for the generous support from our sponsors and partners — we cannot do this important work without you. Because of your support, SWHR is able to continue advocating for prioritized investments in women’s health research and supports innovation and investment in therapies, diagnostics, and devices, with the ultimate goal of improving gender equity, ending health disparities, and improving and transforming women’s health across the lifespan.

Again, we would like to thank our sponsors, partners, and guests for your ongoing support and for your work to improve women’s health. Enjoy the evening!

Sincerely,

Kathryn G. Schubert, MPP, CAE
President and Chief Executive Officer

#ScienceWillWin
EVENING ACTIVITIES

Cocktail Reception
6:00 P.M.

President’s Welcome and Opening Remarks
7:00 P.M.

Dinner
7:30 P.M.

Awards Presentation
8:00 P.M.

Closing Remarks
9:00 P.M.

The toughest challenges. The most advanced science.

We fight the toughest health challenges with advanced science, putting our passion to work where the need is greatest. Because our purpose as a global biopharmaceutical company is to make a remarkable impact on people’s lives.

It takes all of us to turn possibilities into medicine that reaches millions. So we partner with governments, academic institutions, scientific and advocacy groups to make it happen. Together, we’re inventing the future of medicine.

Learn more at abbvie.com

Mission
SWHR is a national nonprofit dedicated to improving women’s health through science, policy, and education.

Vision
Make women’s health mainstream.
Diana Bianchi, MD, is director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, (NICHD) where she oversees an annual budget of about $1.5 billion in support of NICHD’s mission to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. Bianchi was the Health Public Service Visionary Award Winner during SWHR’s 2020 Annual Awards event.

Bianchi received her MD from Stanford University School of Medicine and her postgraduate training in pediatrics, medical genetics and neonatal-perinatal medicine at Boston Children’s Hospital and Harvard Medical School. Bianchi’s research focuses on prenatal genomics with the goal of advancing noninvasive prenatal DNA screening and diagnosis to develop new therapies for genetic disorders that can be administered prenatally.

Wanda Barfield, MD, MPH, FAAP, is Director of the Division of Reproductive Health (DRH) within the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) at the Centers for Disease Control and Prevention (CDC). She is a retired Assistant Surgeon General in the U.S. Public Health Service.

As DRH Director, Barfield leads efforts to provide optimal and equitable health to women, infants, and families through improved surveillance and applied public health research during the critical junctures of population health—pregnancy, infancy, and adolescence. Through building and strengthening strategic partnerships with multiple organizations, her division currently leads several activities to monitor: maternal mortality and severe maternal morbidity, infant mortality and morbidity due to SIDS/SUID and preterm birth; the impact of emerging threats among pregnant/postpartum women and their infants (opioids, disasters, COVID-19); and women’s reproductive health issues ranging from contraception and teen/unintended pregnancy, to infertility and assisted reproductive technology.

She received her medical and public health degrees from Harvard University, completed a pediatrics residency at Walter Reed Army Medical Center, and a neonatal-perinatal medicine fellowship at Harvard. Barfield is a Professor of Pediatrics, at the Uniformed Services University. She continues to provide clinical care to premature and other critically ill newborns.
Shontelle Dodson, PharmD, is the Senior Vice President and Head of US Medical Specialties Business Unit at Astellas and has extensive clinical and research experience in the health care and pharmaceutical industries. She previously served as Senior Vice President and Head of Medical Affairs Americas at Astellas. She currently serves as the SWHR Board Chair.

After several years of service in direct patient care at the Department of Veterans Affairs, Dodson spent 11 years at Pfizer, Inc. in various leadership roles, including the U.S. Viagra Medical Team Leader and Senior Director, Group Leader supporting the urology and respiratory franchise. Following her work with Pfizer, Dodson served as Vice President of Medical Affairs at GTx Inc. In this capacity, she led the Phase 3 clinical development of a selective androgen receptor modulator for the prevention and treatment of muscle wasting in patients with cancer, including key economic and health outcomes assessments to support product utilization and valuation. Under her leadership at Astellas, the health outcomes group has pioneered multiple, innovative real world data projects, including two national registries in prostate cancer and overactive bladder, as well as partnered research with leading managed care and academic organizations.

She has received multiple awards for leadership and innovation during her career, including the National Healthcare Business Women’s Association Rising Star. Dodson holds a Doctor of Pharmacy degree from Mercer University School of Pharmacy and completed a post-doctoral residency at the Department of Veterans Affairs Medical Center in Nashville, Tenn.

Pfizer is being honored for its extraordinary efforts to develop a COVID-19 vaccine along with partner BioNTech just months into a global pandemic. In an ever-evolving global health pandemic, the development of this vaccine is a triumph for science and research. Pfizer has supported SWHR and its work to improve health care for women across the lifespan, disease states, and health conditions since SWHR was founded 32 years ago.

Judy Sewards will accept the award on behalf of Pfizer. Judy Sewards serves as Vice President, Head of Clinical Trial Experience for Pfizer’s Global Product Development organization. In this role, she leads cross functional teams in the creation and activation of new communications and services to build trusted relationships with investigator site partners and deliver a convenient and comfortable experience for clinical trial participants. She played a critical role on the COVID-19 vaccine operations team stewarding all investigator site and trial volunteer communications for the study, including overall recruitment efforts, and building awareness of and educating on the importance of participation within diverse communities. Prior to this, Seward was Vice President, Head of Digital Strategy and Data Innovation responsible for setting and activating new digital and big data strategies to help Pfizer meet business and customer needs in the future health landscape. She has been with Pfizer over 10 years and has held a variety of leadership roles across marketing and innovation.

Before joining Pfizer, Seward led insights, brand strategy, and advertising for Merrill Lynch Global Wealth Management. Her other diverse experiences range from tech start-up to advertising and management consulting. Seward received her bachelor’s degree from Smith College, where she also served as a member of the Board of Trustees.
Laura Cohen is the Associate Vice President for Environment Shaping in Eli Lilly and Company’s Neuroscience Corporate Affairs group where she focuses on policy, access, and reimbursement issues for Alzheimer’s disease therapeutics, diagnostics, and screening. Previously, Cohen was the head of environment shaping and health policy for Lilly’s Immunology business unit where she worked across dermatology, rheumatology, and gastroenterology. Before joining Lilly, Cohen practiced law in several large law firms, including Sidley Austin, LLP, was an in-house counsel for a health insurance company where she focused on regulatory and government affairs issues; and began her career in health policy at Brigham and Women’s Hospital in Boston, Mass. Cohen holds a BA with honors from Brandeis University in History and Health Policy and a JD with honors from Suffolk Law School.

Sudip Parikh, PhD, became the 19th chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals in January 2020. Parikh has spent two decades at the nexus of science, policy, and business. Immediately prior to joining AAAS, Parikh was senior vice president and managing director at DIA Global, a neutral, multidisciplinary organization bringing together regulators, industry, academia, patients, and other stakeholders interested in healthcare product development. He led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies not amenable to existing regulations.

An active member of the scientific advocacy community, Parikh serves as a board member and officer for several impactful organizations, including Research!America, Friends of Cancer Research, and ACT for NIH. He has received multiple public service awards, including recognition from the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation.
Check out some of SWHR's latest patient toolkits!

See all of SWHR’s resources at swhr.org
Kaveeta Vasisht, MD, PharmD is the Associate Commissioner for Women’s Health at the U.S. Food and Drug Administration (FDA). She is responsible for directing the Office of Women’s Health at the FDA. Under her leadership, the Office works to advance the health of women through scientific programs, policy development, research, education, and outreach.

Prior to joining the Office of Women’s Health, Vasisht served as the Deputy Director for the Division of Clinical Trial Quality in the Office of Medical Policy in the Center for Drug Evaluation and Research. She has led multi-stakeholder international collaborations and policy development that are critical to the Agency’s approach to improving clinical trial quality and methodologies. She has worked to promote the inclusion of diverse populations in clinical trials. Vasisht began her career at the FDA in the Division of Metabolism and Endocrine Products, Office of New Drugs, where she served as the clinical expert on multidisciplinary teams in the review and evaluation of scientific data to make regulatory decisions regarding risk-benefit assessments on the safety and effectiveness of therapeutics to treat endocrine conditions for the U.S. population.

Vasisht is board certified in both internal medicine and adult endocrinology and holds a Doctor of Pharmacy degree. She completed her internal medicine training as well as her fellowship training in adult endocrinology, diabetes, and metabolism at the University of Chicago Hospitals, where she also served as a clinical instructor of medicine. She has completed a hospital pharmacy practice residency. Vasisht continues to practice endocrinology in a volunteer clinic. She obtained her medical degree from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. Vasisht combines her clinical experience and academic training with her diverse regulatory background to further advance FDA’s mission to protect, promote, and advance the health of women.

A native of the District of Columbia, Ward grew up in Marshall Heights and the H Street Corridor in Northeast. He lived through the 1968 riots and documented his experiences on News4 as part of the station’s 40th anniversary coverage. Ward attended HD Woodson High School and the University of Maryland.

Ward’s journalism career began in radio. He worked for WPFW, WAMU, and WTOP, covering major stories such as the Iran-Contra hearings, the Sept. 11 attack on the Pentagon, and the Washington-area sniper shootings.

When Ward made the move to television reporting, his first job was at WKBW-TV in Buffalo. He returned to Washington in 2006 and began reporting for News4.
SHWR’s Policy Advisory Council

The Policy Advisory Council is a forum for thought leaders in senior-level policy, advocacy, government and regulatory affairs, and commercial roles at industry, nonprofit, and other health care stakeholder organizations to support emerging research and public policy that will improve health care for women. Members have an opportunity to work collaboratively to develop positions, promote research, and create materials that benefit women’s health.

SWHR’s policy efforts focus on three key areas:

- **Access and Value** — coverage and payment policy, health care value assessment
- **Innovation** — patient engagement in research and development, advocating for the prioritized investment in women’s health research
- **Regulation** — drug, diagnostic, and device regulatory modernization

2022 Women’s Health Policy Agenda

Despite the progress in women’s health since SWHR was founded in 1990, we still have much to accomplish in order to ensure the optimal health of all women nationwide. Now is the time to propel women’s health forward through policy action. SWHR’s annual Women’s Health Policy Agenda outlines policies that we support across five key areas: public health, research & clinical trials, lifespan issues, coverage & access, and biomedical workforce.
ALZHEIMER'S DISEASE

Two-thirds of Alzheimer’s patients are women, and Alzheimer's disease is the fifth leading cause of death in women. SWHR’s new initiative, The Impact of Alzheimer's Disease on Women as Patients and Caregivers: A Call to Action, builds on the foundational scientific, policy, and educational work that SWHR has conducted over the last decade. With recent innovation in diagnostics and therapeutics in Alzheimer’s disease, we need to address barriers to care access and the growing disparities with respect to diagnosis, treatments, and care for people with Alzheimer’s through science and policy. For women in particular, these conversations must recognize the needs of unpaid caregivers and the impact Alzheimer’s has on women as both caregivers and as possible patients.

AUTOIMMUNE DISEASES AND BARRIERS TO ACCESS TO CARE

Eighty percent of people with autoimmune diseases are women due to variation within the sex chromosomes and hormonal changes. Currently, there are no known cures for most autoimmune diseases. An estimated 4.5% of the world’s population and an estimated 8% of the U.S. population have at least one autoimmune disease; they are among the leading causes of death for young- and middle-aged women. This program is designed to address utilization management policies like step therapy and prior authorization that create barriers to access and affordable care for individuals with autoimmune diseases — increasing health care disparities, inequities, and negative outcomes for patients.

BONE HEALTH

About 54 million Americans have low bone mass, placing them at increased risk for osteoporosis. Of the estimated 10 million Americans with osteoporosis, 80% are women. About one in two women over age 50 will break a bone because of osteoporosis. A woman’s risk of breaking a hip is equal to her risk of breast, uterine, and ovarian cancer combined, making osteoporosis a huge area of need in women’s health. Osteoporosis is a health issue that impacts women across the spectrum — white and Asian women are at highest risk, with 20% risk; while Hispanic women, at 10%, and Black women, at 5%, have a lower yet still significant risk. Breaking a bone is a serious complication of osteoporosis, especially with older patients. Twenty percent of seniors who break a hip die within one year from either complications related to the broken bone or the surgery to repair it. Many patients require long-term nursing home care. This program is a call to action, moving from a ‘Break and Fix’ to a ‘Predict and Prevent’ model of women’s bone health care.

COALITION TO ADVANCE MATERNAL THERAPEUTICS (CAMT)

SWHR will oversee the administration of the Coalition to Advance Maternal Therapeutics (CAMT) beginning in 2022. The CAMT was launched in 2014 with the goal of better understanding the safety and efficacy of prescription drugs, therapeutics, and vaccines used during pregnancy and breastfeeding. The CAMT and its member organizations are committed to raising awareness among policymakers and industry about the need to include pregnant and lactating women in clinical trials, where appropriate, to close the gaps in knowledge, and ultimately improve the health of women and their families. The CAMT Steering Committee includes the American Academy of Pediatrics, American College of Obstetricians & Gynecologists, March of Dimes, Society for Maternal-Fetal Medicine and SWHR. Its membership is comprised of nonprofits, medical societies, researchers and includes a new corporate advisory council of maternal health industry leaders.
**ENDOMETRIOSIS**

Endometriosis affects an estimated one in 10 women in the United States. It can develop in any girl or woman after the onset of menstruation, but it is most commonly diagnosed in women in their 30s and 40s. Endometriosis is most prevalent among Asian women, who are more than 50% more likely to be diagnosed with endometriosis than white women. The pain of endometriosis can be devastating, and an endometriosis diagnosis often comes with physical, emotional, and financial burdens. Patients living with endometriosis experience an average of 6.3 hours of lost work productivity and 4.9 hours of lost home productivity per week. Endometriosis is also considered to be the biggest cause of infertility in women. The normalization of women’s pain and the stigmatization of menstrual issues have resulted in a lack of scientific innovation and public awareness for endometriosis, uterine fibroids, and related conditions. This program raises awareness of the gaps in research, diagnosis, treatment, and care for these gynecologic diseases and related symptoms.

**FERTILITY OPTIONS**

Nearly one in eight couples in the United States have trouble getting pregnant or sustaining their pregnancy. While infertility occurs equally in men and women, women tend to bear a disproportionate focus and burden in treatment and management. Treatment options span from medications to invasive surgery and assisted reproductive technologies. About 12% of women ages 15 to 49 have received some type of infertility service. Women want fertility options that offer better outcomes for women and babies, are accessible and cost-effective, minimally invasive, improve health equity, and reduce disparities for all women who want to become mothers. This program explores the risks and benefits of different fertility options for women and their families.

**LUPUS**

An estimated 1.5 million Americans and at least 5 million people globally have a form of lupus. Ninety percent of people with lupus are women between the ages of 15 and 44. An estimated 16,000 new cases are diagnosed each year. Black women are three times more likely to get lupus than white women, and the disease is also more common in Hispanic, Asian, and Native American and Alaska Native women than white women. Lupus nephritis — inflammation of the kidney — is one of the most serious complications of systemic lupus erythematosus. Kidney damage is one of the more common health problems caused by lupus, and over time up to 60% of lupus patients will develop lupus nephritis. Lupus nephritis is more common in women than in men, and there is an even higher prevalence and severity of the disease among African American, Asian, and Hispanic women, between ages 15 and 44, who tend to develop the disease earlier and experience more serious complications. This program addresses disparities in lupus diagnosis, treatment, and access to care among subpopulations of women, with a goal to identify gaps in knowledge, research, education, and policy and to provide recommendations for improving health equity and patient outcomes.

**MENOPAUSE**

With life expectancy increasing, many women will spend a third to half of their lives postmenopausal. Most women experience multiple symptoms of menopause, including hot flashes, night sweats, bone loss, mood swings, depression, anxiety, and genitourinary syndrome. This program raises awareness of knowledge gaps and unmet needs related to the menopausal transition across areas of education, clinical care, research, and policy. This program provides information on the stages of menopause: perimenopause, menopause, and post-menopause; treatments for symptoms; health risks from diseases and conditions; healthy living and wellness strategies for women going through this life stage; mental wellness; and the stigma of menopause and aging.
NARCOLEPSY

Narcolepsy is a debilitating condition that affects daily activities and can harm the health and economic well-being of patients; it can significantly reduce their quality of life as it is a lifetime chronic condition. Often people with narcolepsy experience challenges with employment, school, caring for their families, socially, and in relationships. Although narcolepsy affects both males and females almost equally, for women, who are the most often the primary family caregiver, these challenges can be even more difficult. The stigma associated with narcolepsy can lead to social withdrawal and isolation, contributing to mental health disorders and adversely impacting a person’s life. This program addresses knowledge gaps, unmet needs, burden of disease, medication adherence, and patient disease identification and diagnosis that intended to improve health outcomes and the quality of life for women with narcolepsy.

NONINVASIVE PRENATAL SCREENING

Advancements in noninvasive prenatal screening (NIPS) can benefit women’s health and highlight the need for women — regardless of risk, age, race/ethnicity, or health insurance coverage — to have access to appropriate screening technologies to support their family planning and reproductive plans. This program explores how access to innovations in NIPS may benefit individuals and families who are pregnant or planning to become pregnant. SWHR is building on the foundational work from year one of the genetic screening program and continuing engagement with diverse stakeholders to eliminate barriers to access and reduce disparities in noninvasive prenatal screening.

PSORIATIC ARTHRITIS

More than 8 million Americans and 125 million people worldwide (2-3% of the total population) have psoriasis. Psoriasis prevalence in African Americans is 1.5% compared to 3.6% of Caucasians. Psoriasis is likely to be under-diagnosed among African Americans and other individuals with darker skin of color due to differences in clinical presentation. An estimated 10-30% of people with psoriasis also develop psoriatic arthritis. Of those, 85% develop the skin disease before the joint disease. Nearly 40% of people with psoriatic arthritis report that the disease is a large problem in their everyday life. Although women and men are equally afflicted by psoriatic arthritis, women are less likely to achieve remission in their disease and don’t respond well to certain treatments. This program engages in scientific, policy, and educational efforts to address the significant health, social, and economic impacts of psoriatic arthritis on women’s health across the lifespan.

UTERINE FIBROIDS

Uterine Fibroids (non-cancerous growths in and around the uterus) are one of the most common gynecological conditions nationwide, affecting an estimated 26 million women ages 15 to 50 in the United States. Despite their pervasiveness, this estimate, as well as other fibroids statistics, is thought to be underestimated because women so often go undiagnosed or may not seek medical care for their symptoms. This program was launched to address the impact of uterine fibroids on women’s health across the lifespan, especially disease disparities and stigma experienced by women living with fibroids. The program engages stakeholders on the burden of this disease and promotes science-based health care policies to improve uterine fibroid patient outcome.

VALUE OF DIAGNOSTICS IN WOMEN’S HEALTH

There are more than 100 diagnostic tests and procedures available for detecting diseases and monitoring their progression, and diagnostic tools can help guide treatments, inform patient decision-making, and ultimately improve health outcomes. This program provides an opportunity to highlight the importance and value of innovative diagnostics to improve health outcomes for women across the life span and across disease states and conditions. Designed as a series of educational webinars, these conversations focus on diagnostics for women in: bone health/osteoporosis, breast cancer, cervical cancer, fertility, ovarian cancer, and sexually transmitted infections.

WOMEN’S HEALTH EQUITY INITIATIVE

Women in the United States experience health disparities throughout their lifespans as a result of their gender, historic health inequities in the health care system, and socioeconomic conditions. Launched in 2022, the SWHR Women’s Health Equity Initiative highlights statistics on women’s health in the United States and aims to engage communities on solutions to improve health equity across multiple disease states, conditions, and life stages. The first phase of the Initiative is focused on Alzheimer’s disease, bone health, maternal health, and menopause. Through the creation of a unique roadmap and video testimonials, featuring caregivers, patients, and clinicians across the United States, SWHR is working to end women’s health disparities based on age, race, ethnicity, geography, and among caregivers. To learn more and support the Women’s Health Equity Initiative, visit www.swhr.org/healequity.

SWHR CURRENT PROGRAMS

NARCOLEPSY

Avadel

NONINVASIVE PRENATAL SCREENING

illumin

PSORIATIC ARTHRITIS

Lilly

UTERINE FIBROIDS

Roche

VALUE OF DIAGNOSTICS IN WOMEN’S HEALTH

WOMEN’S HEALTH EQUITY INITIATIVE

SWHR CURRENT PROGRAMS

SWHR CURRENT PROGRAMS

@SWHR  ·  23  ·  #SWHRGala
We care about women and women’s health. And about doing our part to help them stay strong and healthy. And we are proud to support the work of SWHR.

Hologic.com

The Society for Women’s Health Research’s Women’s Health Equity Initiative highlights data on women’s health in the United States and aims to provide solutions to improve health equity across diseases, conditions, and life stages.

To learn more, visit www.swhr.org/healthequity
Horizon is proud to support the Society for Women’s Health Research

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. At Horizon, we believe science and compassion must work together to transform lives.

Redefining Care FOR WOMEN

We congratulate the 2022 Society for Women’s Health Research Honorees and applaud the organization for their decades-long commitment to improving women’s health through science, policy, and education.

At Myovant, we believe a transformative effort is needed to make significant progress for women. That’s why we are working across sectors to elevate women’s health and bring much-needed attention to uterine health conditions because when she moves forward, we all move forward.
**EXECUTIVE COMMITTEE**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kathryn G. Schubert, MPP, CAE</td>
<td>President and CEO Society for Women’s Health Research Ex Officio</td>
</tr>
<tr>
<td>Shontelle Dodson, PharmD</td>
<td>Board Chair Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Jenelle S. Krishnamoorthy, PhD</td>
<td>Merck &amp; Co. Inc.</td>
</tr>
<tr>
<td>Yonas G. Fsahaye, MBA</td>
<td>Chief Financial Officer</td>
</tr>
<tr>
<td>Joy S. Braun, MPA, MA</td>
<td>Vice President, Strategic Initiatives &amp; Partnerships</td>
</tr>
<tr>
<td>Lindsey Horan, MA</td>
<td>Chief Advocacy Officer</td>
</tr>
<tr>
<td>Irene O. Aninye, PhD</td>
<td>Chief Science Officer</td>
</tr>
<tr>
<td>Emma Bixler</td>
<td>Development Coordinator</td>
</tr>
</tbody>
</table>

**MEMBERS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Carey</td>
<td>Organon and Co.</td>
</tr>
<tr>
<td>Patti Compton, MS Pfizer</td>
<td></td>
</tr>
<tr>
<td>Anne B. Cropp, PharmD</td>
<td>Early Access Care LLC</td>
</tr>
<tr>
<td>Linda G. Griffith, PhD</td>
<td>Massachusetts Institute of Technology</td>
</tr>
<tr>
<td>Dawn Halluff, MBA Ideal Protein</td>
<td></td>
</tr>
<tr>
<td>Judette Louis, MPH, MD</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>Erika Miller, JD CRD Associates</td>
<td></td>
</tr>
<tr>
<td>Michael Ybarra, MD PhRMA</td>
<td></td>
</tr>
<tr>
<td>Florence Hasselton, MD, PhD</td>
<td>Founding Honorary Board Director</td>
</tr>
<tr>
<td>Erika Miller, JD CRD Associates</td>
<td></td>
</tr>
<tr>
<td>Michael Ybarra, MD PhRMA</td>
<td></td>
</tr>
<tr>
<td>Florence Hasselton, MD, PhD</td>
<td>Founding Honorary Board Director</td>
</tr>
<tr>
<td>Erika Miller, JD CRD Associates</td>
<td></td>
</tr>
<tr>
<td>Michael Ybarra, MD PhRMA</td>
<td></td>
</tr>
<tr>
<td>Florence Hasselton, MD, PhD</td>
<td>Founding Honorary Board Director</td>
</tr>
<tr>
<td>Erika Miller, JD CRD Associates</td>
<td></td>
</tr>
<tr>
<td>Michael Ybarra, MD PhRMA</td>
<td></td>
</tr>
<tr>
<td>Florence Hasselton, MD, PhD</td>
<td>Founding Honorary Board Director</td>
</tr>
</tbody>
</table>

**SWHR STAFF**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kathryn G. Schubert, MPP, CAE</td>
<td>President and CEO Society for Women’s Health Research Ex Officio</td>
</tr>
<tr>
<td>Yonas G. Fsahaye, MBA</td>
<td>Chief Financial Officer</td>
</tr>
<tr>
<td>Joy S. Braun, MPA, MA</td>
<td>Vice President, Strategic Initiatives &amp; Partnerships</td>
</tr>
<tr>
<td>Lindsey Horan, MA</td>
<td>Chief Advocacy Officer</td>
</tr>
<tr>
<td>Irene O. Aninye, PhD</td>
<td>Chief Science Officer</td>
</tr>
<tr>
<td>Monica Lefton</td>
<td>Communications Manager</td>
</tr>
<tr>
<td>Carolyn McPhee, MPH</td>
<td>Manager Science Programs</td>
</tr>
<tr>
<td>Gabriella Watson, MS</td>
<td>Science Programs Coordinator</td>
</tr>
<tr>
<td>Emma Bixler</td>
<td>Development Coordinator</td>
</tr>
<tr>
<td>Gwen Feeny, JD Science Policy Fellow</td>
<td></td>
</tr>
<tr>
<td>Katelyn Black</td>
<td>Science Program Fellow</td>
</tr>
</tbody>
</table>

**SWHR BOARD OF DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kathryn G. Schubert, MPP, CAE</td>
<td>President and CEO Society for Women’s Health Research Ex Officio</td>
</tr>
<tr>
<td>Shontelle Dodson, PharmD</td>
<td>Board Chair Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Jenelle S. Krishnamoorthy, PhD</td>
<td>Merck &amp; Co. Inc.</td>
</tr>
<tr>
<td>Irene O. Aninye, PhD</td>
<td>Chief Science Officer</td>
</tr>
<tr>
<td>Emma Bixler</td>
<td>Development Coordinator</td>
</tr>
<tr>
<td>Gwen Feeny, JD Science Policy Fellow</td>
<td></td>
</tr>
<tr>
<td>Katelyn Black</td>
<td>Science Program Fellow</td>
</tr>
</tbody>
</table>

At **Organon**, our goal is to deliver innovation, improve access, and expand choice to help address therapeutic gaps in women’s health and ultimately improve the lives of women globally.

Organon proudly supports the Society for Women’s Health Research in their vision to make women’s health mainstream.
Turning Innovative Science into Value for Patients

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide. Every day, we work together to address unmet medical needs and help people living with cancer, overactive bladder, heart disease, and transplants, among other conditions. We remain dedicated to meeting patients’ needs, and our support for them will never waver.

At Astellas, we’re focused on making changing tomorrow a reality.

www.lilly.com

LILLY SALUTES

the Society for Women’s Health Research as they celebrate achievements, advancements, and innovations in women’s health.